抄録
Introduction
Gefitinib is a molecularly targeted drug for oral administration, a selective epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI). It is effective for patients with lung cancer who have EGFR mutation and enables long-term survival of
patients with advanced disease.
Case presentation
An 84-year-old Asian female with lung cancer (adenocarcinoma, cT4N3M1b stage IV PUL BRA OSS ADR) was treated by
gefitinib for two years. The primary tumor was markedly reduced, and bone metastasis had almost disappeared. However, the
patient became unconsciousness with general edema and died two days after falling unconsciousness. In the autopsy, it was
diagnosed as infectious cerebral thromboembolism due to infectious endocarditis. The cause of death was cardiac tamponade.
Conclusions
While long-term survival can be expected in patients with advanced lung cancer by molecular-targeted agents, cautious
management is warranted for complications, the same as for the primary disease.
